Adapt Pharma Operations v. Teva Pharmaceuticals USA, Inc., No. 20-2106 (Fed. Cir. Feb. 10, 2022)

From the Opinion

The passage below is extracted verbatim from the opening of the document. It has not been editorially summarized — consult the full opinion for the court's complete reasoning.

Adapt Pharma Operations Limited, Adapt Pharma, Inc., Adapt Pharma Limited, and Opiant Pharmaceuticals, Inc. (collectively, “Adapt”) appeal the United States Dis- trict Court for the District of New Jersey’s final judgment of invalidity. After a two -week ben ch trial, the district court determined that the asserted claims of U.S. Patent Nos. 9,468,747; 9,561,177; 9,629,965; and 9,775,838 (collec- tively, the “patents -in-suit”) would have been obvious in view of the prior art .